[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier le Mans\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":439},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,44,71,94,116,142,168,198,227,253,275,299,323,345,371,395,418],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100054109","phase-2-incremental-dialysis-and-diet-for-a-better-life-experience-100054109",false,"NCT07699627","INCREmental DIalysis and Diet for a Better Life Experience","INCREDIBLE: INCREmental DIalysis and Diet for a Better Life Experience; Clinical Relevance of an \"add-on\" Ketosteril Supplementation on Incremental Haemodialysis Period in Incident Haemodialysis Patients. An Exploratory Randomized Controlled Trial","INCREDIBLE","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older)\n* Able and accepting to give informed consent\n* Starting iHD in the Centre Hospitalier Le Mans\n\nExclusion Criteria:\n\n* Denying informed consent\n* Acute kidney injury (AKI)\n* Life expectancy of less than 3 months, or kidney transplantation scheduled within 3 months\n* Cognitive impairment severe enough to limit understanding and acceptance of the study\n* Impossibility to regain kidney function (bilateral nephrectomy, documented irreversible complete destruction of the kidney tissue)\n* Patient with genetic disease affecting amino acid metabolism\n* Hypercalcemia defined as calcemia beyond the upper limit of normality according to the laboratory where the test is performed and persisting for at least one month\n* Hypersensitivity to the active substances or to any of the excipients of Ketosteril\n* Non-compliance to dialysis prescription\n* Previous enrolment in a randomized study using Ketosteril\n* Currently enrolled in another interventional clinical trial\n* Protected by law (patient under guardianship, minor, prisoner, pregnant or breastfeeding woman, …)","ALL","18 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Previous studies suggest that the supplementation of essential amino acids and ketaoacids may prolong the duration of the incremental phase of peritoneal dialysis. There is no data on incremental haemodialysis patients. Such data would be highly needed to support the management of haemodialysis patients in the transition phase from \"pre-dialysis\" to \"full dose\" dialysis. In this context, investigator proposed a randomized \"add on\" trial, to evaluate the effect of the addition of Ketosteril to the usual nutritional plan to patients who start haemodialysis in incremental way.",[27],"Incremental Haemodialysis",[29,30],"ketosteril","incremental haemodialysis","NOT_YET_RECRUITING","2026-07-08",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":21},"2026-09-01",{"date":39,"type":21},"2030-09-01",{"name":41,"class":42},"Centre Hospitalier le Mans","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100616157","impact-of-early-rupture-of-the-residual-membrane-on-latency-before-labour-begins-100616157","NCT07301957","Impact of Early Rupture of the Residual Membrane on Latency Before Labour Begins","RESIRUPT","Inclusion Criteria:\n\n* Women over 18 years of age\n* Single foetal pregnancy, cephalic presentation\n* diagnosis of membrane rupture with persistence of one membrane and absence of immediate spontaneous labour.\n* Person affiliated with or beneficiary of a social security scheme\n* Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research).\n\nExclusion Criteria:\n\n* Minor patient\n* patient under guardianship\u002Fcuratorship,\n* multiple pregnancy, pregnancy with foetal death\n* non-cephalic presentation\n* gestational age less than 37 weeks,\n* rupture of membranes more than 12 hours ago\n* contraindication to vaginal deliver\n* meconium-stained amniotic fluid,\n* clinical signs suggestive of intrauterine infection (maternal hyperthermia \\>38°C, maternal and\u002For foetal tachycardia, purulent amniotic fluid),\n* cervix not accessible for artificial rupture\n* vaginismus\n* contraindication to a potential expectant management\n* indication for induction for another reason","FEMALE",{"count":53,"type":21},130,[55],"NA","Approximately 25% of patients experience premature rupture of membranes before labour. Of these patients, 82% will give birth within 24 hours and 97% within 48 hours.\n\nPatients who do not go into labour spontaneously will be induced 24 or 48 hours after their membranes rupture, depending on the centre.\n\nDuring this period, they are hospitalised in the obstetrics department. The presence of a residual membrane appears to prolong the latency period before labour begins and the rate of induction, according to a pilot study conducted by investigator.\n\nNo study specifically addresses this topic. The various studies on \"Rupture of Membranes Before Labour\" assess its frequency of occurrence or the time before considering induction. They also assess the occurrence of maternal-foetal infection. This is no longer of interest today, as antibiotic prophylaxis has significantly reduced maternal-foetal infections.\n\nInvestigator would therefore like to assess the impact of additional rupture of the residual membrane upon the patient's admission on the latency before labour and the induction rate (for membrane rupture exceeding 48 hours.",[58],"Prelabor Rupture of Membranes",[60],"prelabor rupture of membranes","RECRUITING","2026-06-30",{"date":64,"type":35},"2026-07-01",{"date":66,"type":35},"2026-03-24",{"date":68,"type":21},"2028-03-24",{"name":41,"class":42},2,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":43},"100461541","interest-of-the-virtual-reality-as-an-analgesic-support-and-in-the-management-the-pre-procedural-anxiety-in-rheumatology-100461541","NCT05289999","Interest of the Virtual Reality as an Analgesic Support and in the Management the Pre-procedural Anxiety in Rheumatology","REAVIR","Inclusion Criteria:\n\n* Adult patient (age ≥ 18 years)\n* Hospitalized in a day-hospitalization department at the General Hospital of Le Mans\n* For whom a diagnosis of radiculalgia with a duration of less than 6 months is made, for which the imaging is compatible with the symptoms according to the clinician's interpretation\n* For whom the indication of at least 2 epidural injections by the way of the sacrococcygeal hiatus is retained\n* Having never experienced an epidural injection through the sacrococcygeal hiatus\n* Patient able and willing to answer the auto-administered surveys\n* Person affiliated or beneficiary of a social security\n* Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research) after oral and written information\n\nExclusion Criteria:\n\n* Patient with comorbidity of epilepsy\n* Patient with a contraindication to performing epidural injections through the sacrococcygeal hiatus\n* Patient suffering from blindness and \u002F or deafness\n* Person with a known significant intolerance towards the use of screens and \u002F or virtual reality devices\n* Patient receiving benzodiazepines and \u002F or other sedative treatment\n* Patient with a known depressive disease followed by a psychiatrist\n* Pregnant, breastfeeding or parturient woman\n* Person deprived of liberty by judicial or administrative decision\n* Person under forced psychiatric care\n* Person subject to legal protection\n* Person unable to express consent\n* Patient who had participated in an interventional study during the last 30 days\n* Severely impaired physical and \u002F or mental health which, according to the investigator, may affect the compliance of the study participant",{"count":20,"type":21},[55],"As a part of the current rheumatological practice skills, epidural injections through the sacrococcygeal hiatus take part in the strategy for managing radicular diseases. This technical act is easily performed in an outpatient context since it is a brief procedure, performed under clinical and ultrasound control, with good tolerance. Nevertheless, epidural injections by the way of the sacrococcygeal hiatus can be responsible of anxiety for the patient and meet the definition of pain induced by treatment. Among the non-pharmacological methods that can be offered to the patient in this context, hypnosis and distraction allow psycho-corporal support acting on certain factors influencing the painful experience of the gesture: duration of the gesture, calm and pleasant environment, etc... That is the context in which the use of virtual reality is of interest. Its use in supporting procedures generating induced pain has already been evaluated in several studies, in particular in the fields of surgery and anaesthesiology. The use of a virtual reality device also seems suitable in the context of epidural injections, but this theoretical and plausible interest remains to be demonstrated. To our knowledge, the literature on the use of a virtual reality headset to support invasive procedures in rheumatology remains poorly developed. The objective of this study is therefore to assess the interest of using a virtual reality headset in the support of pain relief and the management of peri-procedural anxiety when performing epidural injections through the sacrococcygeal hiatus.",[82],"Radiculopathy",[84,85,86,87],"epidural injection","virtual reality","pain management","performance anxiety",{"date":64,"type":35},{"date":90,"type":35},"2022-06-10",{"date":92,"type":21},"2026-12-31",{"name":41,"class":42},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":43},"100423929","adapted-physical-activity-in-patients-with-lower-limb-peripheral-arterial-disease-100423929","NCT04800276","Adapted Physical Activity in Patients With Lower Limb Peripheral Arterial Disease","Adapted Physical Activity in Patients With Lower Limb Peripheral Arterial Disease (ACTIV'AO)","ACTIV'AO","Inclusion Criteria:\n\n* Patient with Lower Limb Peripheral Arterial Disease with IPSC \\\u003C 0.90, arterial stenosis in the lower limbs and intermittent claudication\n* No contraindication to physical activity\n* Socially insured patients over 18 ;\n* Patient who has signed the consent form.\n\nExclusion Criteria:\n\n* Severe or unstable cardiopulmonary pathologies, contraindicating exercise training\n* Unstable angina or myocardial infarction \\\u003C3 months\n* Severe rheumatological pathology of the lower limbs\n* Amputee of a lower or upper limb fitted with a device\n* Extensive dermatosis of the lower limbs\n* Known NYHA grade III or IV heart failure\n* Known severe respiratory pathology\n* Parkinson's disease, hemiplegia or paraplegia\n* Adults subject to enhanced protection, deprived of their liberty by judicial or administrative decision\n* Persons unable to consent\n* Be in a period of exclusion from other interventional research.\n* Any event (injury, surgery, etc.) occurring during the protocol period that could have an impact on results.",{"count":20,"type":21},[55],"The prevalence of peripheral arterial disease is 12.2% in France. Intermittent claudication is the most common symtom of this disease. During physical exercise, such as walking, blood oxygen (O2) requirements increase. The development of atherosclerosis in the lower limbs, causes narrowing of the arteries and limits the increase in blood flow required for muscular effort. Patients then experience muscle pain, the intensity of which gradually increases until it forces them to stop. After stopping, the pain subsides and disappears in less than 10 minutes.\n\nThe location of the pain (calves and\u002For thighs and\u002For buttocks) is related to the location of the ischemia (distal in the calf, proximal in the thigh or buttock, or proximo-distal if several locations). This can have different consequences on the biomechanical parameters of walking and muscle activity. To date, the impact of this localization on physical capacity has never been studied.\n\nThese limitations are very disabling and impact the quality of life of patients.\n\nIn addition, poor lower limb performance is associated with higher mortality. Reducing symptomatology and improving functional abilities is therefore a major issue in patients with peripheral arterial disease. This can be achieved through the practice of an Adapted Physical Activity, an essential recommendation in the care of patients with peripheral arterial disease.\n\nOur main hypothesis is that the physical activity rehabilitation protocol \"Activ'AO\" will improve the functional capacities of patients with peripheral arterial disease who have followed the program with the localization of ischemia with a greater consideration than in patients in the group following a \"standard\" APA protocol. Improvements in functional abilities (such as walking) will lead to improvements in quality of life.",[106],"Peripheral Arterial Disease",[106,108,109],"Adapted Physical Activity","maximum walking distance",{"date":64,"type":35},{"date":112,"type":35},"2021-02-11",{"date":114,"type":21},"2026-11-11",{"name":41,"class":42},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":70},"100360929","protecting-kidneys-through-a-low-protein-diet-a-stepwise-multiple-choice-system-approach-100360929","NCT03979534","Protecting Kidneys Through a Low Protein Diet: A Stepwise Multiple-Choice System Approach","ProReRePro","Inclusion Criteria:\n\n* All adult patients followed on the unit for advanced CKD, with Kidney disease stage 4-5 or stage 3 with fast progression and without contraindications.\n\nExclusion Criteria:\n\n* Malnutrition or short life-expectancy\n* Patients aged less than 18 years old\n* Pregnant women,\n* Incapacity to complete the free-consent form,\n* Pateints refusing participation in the study,\n* Patients without healthcare coverage.",{"count":124,"type":21},100,[55],"Nephrology care continues to progress and recommendations are now focused on delaying as much as possible the need for renal replacement therapy (\"intent-to-defer\"strategy). Protein restriction is a valuable tool for stabilizing chronic kidney disease (CKD) and retarding the need for renal replacement therapy, but the best diet to be prescribed is still matter of discussion. This study is aimed at identifying implementation strategies for nutritional management of advanced CKD.",[128],"Chronic Kidney Diseases",[130,131,132,133,134,135],"low-protein diet","pre-dialysis","chronic kidney disease","nutritional care","start of dialysis","incremental dialysis",{"date":64,"type":35},{"date":138,"type":35},"2019-04-01",{"date":140,"type":21},"2028-04-01",{"name":41,"class":42},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},"100621055","prophylactic-anticoagulation-with-heparine-in-critically-ill-patients-with-renal-impairment-100621055","NCT07365644","Prophylactic ANTicoagulation With HEparine in Critically Ill Patients With Renal Impairment","PANTHER","Inclusion Criteria:\n\n* Presence of impaired renal function (one of the two criteria must be met, both criteria may be met):\n\nGlomerular filtration rate (GFR) \\\u003C30ml\u002Fmin\u002F1.7m² according to the MDRD or CKD-EPI formula.\n\nAcute renal failure (observed or presumed increase in creatinine in the last 7 days) KDIGO stage 3 (creatinine ≥3 times baseline creatinine or ≥354 µmol\u002FL (4 mg\u002FdL) or urine output \\\u003C0.3 mL\u002Fkg\u002Fh for ≥24 hours or initiation of extrarenal clearance or anuria for ≥12 hours)\n\n\\- Expected length of stay in intensive care ≥48 hours\n\nExclusion Criteria:\n\n* Age ≤ 18 years\n* Long-term dialysis patient\n* Current or recent hemorrhage during this hospitalization\n* Patient receiving curative anticoagulation or treated long-term prior to admission with curative anticoagulation.\n* Thrombosis present on admission",{"count":150,"type":21},1111,"OBSERVATIONAL","Intensive care patients have an increased risk of venous thromboembolic events (deep vein thrombosis (DVT) and pulmonary embolism (PE)) due to the presence of general risk factors for thrombosis (age, immobilization, obesity, prothrombotic history, etc.), but also risk factors specifically related to their stay in intensive care (sepsis, vasopressors, organ failure, mechanical ventilation, sedation, renal failure, central venous catheters). In addition, these same patients also have an increased risk of hemorrhagic events, mainly associated with coagulation disorders and thrombocytopenia.\n\nGiven this increased risk of thrombosis, it is recommended that heparin thromboprophylaxis be used in intensive care patients in the absence of contraindications.\n\nIn current practice, when faced with a patient with impaired renal function, there is significant heterogeneity in the prescription of thromboprophylaxis between centers and intensive care physicians: some will use enoxaparin, dalteparin, or tinzaparin regardless of renal function, while others will use subcutaneous calciparin or IVSE UFH.\n\nThe PANTHER study is a prospective, multicenter, observational study that aims to evaluate the safety and efficacy of heparin thromboprophylaxis in critically ill patients with renal failure. The goal is to assess whether there is a difference in bleeding risk and thromboprophylaxis efficacy depending on the molecule used.",[154],"Prophylactic Anticoagulation",[156,157,158],"intensive care unit","Prophylactic ANTicoagulation","Renal impairment","2026-01-16",{"date":161,"type":35},"2026-01-26",{"date":163,"type":21},"2026-01-01",{"date":165,"type":21},"2028-02-01",{"name":41,"class":42},15,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":175,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":183,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":197},"100597575","halo-sign-vanishing-time-after-steroids-outbreak-in-gca-patients-100597575","NCT07060274","Halo Sign Vanishing Time After Steroids Outbreak in GCA Patients","Halo-A","Inclusion Criteria:\n\n* Patients aged 50 and over\n* Without legal protection.\n* Meeting GCA classification criteria as defined by ACR 2022.\n* Newly diagnosed with an indication for corticosteroid treatment.\n* Have not yet received corticosteroid treatment for GCA.\n* No contraindication to corticosteroid treatment.\n* Person affiliated with or benefiting from a social security scheme.\n* Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination necessary for the research).\n\nExclusion Criteria:\n\n* Patients with a relapse of Giant Cell Arteritis (GCA).\n* Patients who have previously undergone a temporal artery biopsy (TAB), including for other reasons.\n* Patients who have received oral corticosteroid treatment in the past month or are currently on corticosteroid therapy (excluding hydrocortisone or local corticosteroids).\n* Patients with other types of vasculitis that may constitute a differential diagnosis: presence of antibodies against the cytoplasm of neutrophils (ANCA), positive syphilis serology, positivity of an IGRA test (Interferon Gamma Release Assay).\n* Patients having received immunosuppressive treatment or biotherapy in the month prior to inclusion. If the patient's condition warrants the use of biotherapy or immunosuppressive treatment, its initiation will be delayed until after Day 7 to avoid interfering with the Doppler procedure.","50 Years",{"count":177,"type":21},64,[55],"Giant cell arteritis (GCA) is a rare disease characterized by vasculitis of the large arterial trunks targeting the thoracic aorta and its dividing branches, affecting adults over the age of 50. Vasculitis lesions cause thickening of the arterial wall, visible on temporal artery biopsy (TAB) or vascular imaging (echo-Doppler, angio-CT, angio-MRI, 18FDG PET-CT). This is a severe disease that can lead to blindness. Early diagnosis is essential, so that steroids therapy can be started as soon as possible to prevent complications. Doppler ultrasonography of the temporal arteries provides rapid, non-invasive diagnostic support. However, the recommendations do not specify how soon temporal artery Doppler should be performed after steroids treatment, except that the halo sign would disappear after about 5 days on steroids. Sensitivity seems to be better when the examination is performed early, but the time taken for the halo sign to disappear is unknown. The investigator suggests that the disappearance of the temporal artery halo sign in GCA patients is observed earlier than D14 of steroids treatment usually reported in the literature. He speculates that the sensitivity of the temporal artery Doppler decreases as early as D3 of steroids treatment, and that beyond D7 it is not useful to perform this examination as its sensitivity becomes too low.",[181,182],"Giant Cell Arteritis (GCA)","Doppler Ultrasound",[184,185,186,187,188],"Giant cell arteritis","echo-Doppler","Doppler ultrasonography","Halo sign","steroids","2025-07-01",{"date":191,"type":35},"2025-07-11",{"date":193,"type":21},"2025-09",{"date":195,"type":21},"2027-10",{"name":41,"class":42},6,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":226},"100476664","mean-arterial-pressure-after-out-of-hospital-cardiac-arrest-100476664","NCT05486884","Mean Arterial Pressure After Out-of-hospital Cardiac Arrest","Mean Arterial Pressure After Out-of-hospital Cardiac Arrest: the METAPHORE Randomized Trial","METAPHORE","Inclusion Criteria:\n\n* Admission to ICU following an out-of-hospital cardiac arrest with an initially shockable or non-shockable rhythm ;\n* Sustained ROSC defined as 20 minutes with signs of circulation without the need for chest compressions;\n* Under invasive mechanical ventilation for coma, defined as a Glasgow score ≤ 8\u002F15;\n* Consent from a relative or of a procedure for emergency inclusion.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years ;\n* In-hospital cardiac arrest (first cardiac arrest);\n* Unwitnessed CA with initial rhythm of asystole\n* Delay between ROSC and attempting randomisation \\> 6 hours ;\n* Cardiac arrest in a context of multiple trauma ;\n* Cardiac arrest in a context of hemorrhagic shock or severe hemorrhage necessitating hemostasis (surgery or radiological or endoscopic hemostasis) ;\n* Cardiac arrest secondary to an acute brain disease (ischemic or hemorrhagic stroke, subarachnoid hemorrhage, severe traumatic brain injury) ;\n* Refractory shock :\n\nDefined as a MAP \\\u003C 65 mmHg for more than one hour on norepinephrine or epinephrine at a dose \\> 1 µg\u002Fkg\u002Fmin despite adequate fluid resuscitation ;\n\n* Extracorporeal circulatory support prior to inclusion;\n* Known allergy to norepinephrine or to any of its excipients;\n* Decision to limit care before inclusion ;\n* Modified Rankin score of 4 or 5 before cardiac arrest ;\n* Inclusion in another interventional study in which the principal endpoint is neurological prognosis ;\n* Pregnancy or breast feeding ;\n* Adult patient deprived of freedom or under legal protection (patients under guardianship or curatorship) (article L1121-6 of the French Health Code) ;\n* Non-French speaking;\n* Patient already included in this trial ;\n* Absence of social security cover.",{"count":207,"type":21},1380,[55],"Out-of-hospital cardiac arrest is a public health problem for which overall survival is below 10%. Post-cardiac arrest syndrome is the principal cause of death in intensive care units (ICU), due to refractory shock or brain injuries secondary to anoxia. Brain anoxia is responsible for severe neurological sequelae that may be aggravated by cerebral hypoperfusion during the first few hours after the return of spontaneous circulation. Current recommendations are to ensure that arterial blood pressure is sufficient for the perfusion of organs, but no minimum threshold mean arterial pressure (MAP) has been defined. In practice, most teams target a MAP of at least 65 mmHg. Several observational studies have shown a correlation between MAP and neurological prognosis, patients with a higher initial MAP having a better outcome. Recent pilot studies have demonstrated the feasibility of increasing the target MAP after cardiac arrest, but conflicting results have been obtained concerning patient prognosis. These findings may be explained by changes to the autoregulation of the brain after cardiac arrest, with a shift of the curve towards the right, or its abolition. Cerebral blood flow is dependent on MAP, and a target MAP of 65 mmHg for these patients may result in insufficient brain perfusion. Conversely, a too high MAP might cause brain lesions due to vasogenic edema, hemorrhagic complications or excess perfusion in conditions of diminished brain metabolism. An interventional study is required to evaluate the effect of increasing MAP on neurofunctional outcome after cardiac arrest. Given the data available for brain autoregulation, the correlation between MAP and prognosis, and the risks theoretically associated with a higher MAP, investigator plans to compare a standard threshold of MAP (≥ 65 mmHg) with a high threshold of MAP (≥ 90 mmHg). Investigator hypothesizes that a high MAP within the first 24 hours after cardiac arrest will improve neurofunctional outcome.",[211,212],"Cardiac Arrest","Out-of-hospital Cardiac Arrest (OHCA)",[214,215,216,217],"cardiac arrest","outcome","cerebral blood flow","mean arterial pressure","2025-03-21",{"date":220,"type":35},"2025-03-26",{"date":222,"type":35},"2024-09-28",{"date":224,"type":21},"2028-03-28",{"name":41,"class":42},27,{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":237,"conditions":238,"keywords":240,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":252},"100582108","validation-of-the-har-score-for-prioritization-of-patients-calling-the-emergency-medical-service-for-chest-pain-by-emergency-call-dispatcher-100582108","NCT06859021","Validation of the HAR Score for Prioritization of Patients Calling the Emergency Medical Service for Chest Pain by Emergency Call Dispatcher","Validation of the HAR Score for Prioritization of Patients Calling the Emergency Medical Service for Chest Pain by Emergency Call Dispatcher : Reg-HAR Study","Reg-HAR","Inclusion Criteria:\n\n* Patient of legal age (≥ 18 years)\n* Calling Center 15 from 49, 72 or 37\n* Expressing non-traumatic chest pain, even if this is not the main reason for seeking help.\n\nExclusion Criteria:\n\n* Treatment in departments other than 49, 72 and 37\n* Taken in charge in an emergency department of a private facility in the 49, 72 and 37 départements\n* Poor understanding of the French language\n* Non-affiliated or non-beneficiary of a social security scheme\n* Person deprived of liberty by judicial or administrative decision\n* Person under forced psychiatric care\n* Person subject to a legal protection measure\n* Person unable to express his\u002Fher non-opposition.\n* Follow-up at Day 30 impossible for any reason\n* Person having expressed his\u002Fher opposition to the collection of his\u002Fher data.",{"count":236,"type":21},796,"The lifetime prevalence of chest pain in the general population is 20-40%. The etiologies to be evoked from the outset of management are those of cardiovascular origin, such as acute coronary syndrome (ACS) and pulmonary embolism. ACS is responsible for almost 20% of deaths. Delay in treatment is a major prognostic factor, given the importance of coronary reperfusion.\n\nIn France, one of the first contacts with the healthcare system is the medical regulation assistant (MRA) at the Centre 15. His or her role is to prioritize the call according to the identification of immediate signs of seriousness, and if necessary, to decide autonomously to send a rescue team before medical regulation. Depending on the reason for the call and any signs of seriousness, it prioritizes the call according to the expected response time. In line with current recommendations, all calls for chest pain should be answered by an emergency medical dispatcher (EMR) within 5 minutes. However, 60-90% of chest pain calls are not of cardiovascular origin. Their prioritization could therefore be re-qualified for longer response times.\n\nGiven the frequency of this type of call, a more efficient MRA referral strategy is needed. To achieve this, decision-support tools would be essential.\n\nThe performance of the HAR (History, Age and Risk Factors) score has been recently explored, derived from the HEART score, in a previous single-center prospective study in 2019. It stratifies the risk of a major cardiovascular event (MCE) into low (0 or 1 point), intermediate (2 or 3 points) or high (4, 5 or 6 points).\n\nInvestigator's hypothesis is that the HAR score could be entrusted to MRA, to enable them to optimize the prioritization of patients calling with non-traumatic chest pain, by qualifying low-risk chest pain calls on the one hand, which could be prioritized in P2 SNP, and high-risk calls on the other, making it possible to anticipate the dispatch of an emergency service.",[239],"Chest Pain",[241,242,243],"Chestpain","HAR score","Emergency call","2025-03-19",{"date":246,"type":35},"2025-03-24",{"date":248,"type":21},"2025-05-02",{"date":250,"type":21},"2025-12",{"name":41,"class":42},3,{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":22,"phases":262,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":269,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":43},"100577554","the-impact-of-the-therapeutic-virtual-reality-headset-on-patient-anxiety-in-the-waiting-room-before-flexible-bronchoscopy-in-vigil-100577554","NCT06799806","The Impact of the Therapeutic Virtual Reality Headset on Patient Anxiety in the Waiting Room Before Flexible Bronchoscopy in Vigil","REVA","Inclusion Criteria:\n\n* Adult patients with no age or gender restrictions, seen on an outpatient basis at Le Mans Hospital.\n* In whom bronchial fibroscopy is indicated.\n* Person affiliated with or benefiting from a social security .\n* Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research).\n* Patient able and willing to answer questionnaires\n\nExclusion Criteria:\n\n* Patient refusing to participate in research\n* Patient who has already undergone bronchoscopy in vigil\n* Patient premedicated for bronchial fibroscopy (anxiolytic, etc.)\n* Patients with a history of epilepsy or psychiatric pathology\n* Patient with vertigo\n* Patient uncooperative, demented or unable to tolerate headgear.\n* patient under guardianship or curatorship\n* Patients suffering from blindness or deafness\n* Patient with known significant intolerance to screens and\u002For virtual reality devices\n* Pregnant, nursing or parturient women\n* Unscheduled patients: emergencies, etc.\n* Hospitalized patients",{"count":261,"type":21},80,[55],"Bronchial fibroscopy is a frequently used procedure in the management of pneumology patients, and can be a source of anxiety, particularly while waiting for the examination.\n\nInvestigator's professional experience has shown us that many patients are anxious in the waiting room before a flexible bronchoscopy in vigile.\n\nA great deal of research has been carried out into the use of virtual reality to reduce anxiety and pain during care but shortly before bronchoscopy. The innovative aspect is to target the patient's waiting time for the examination. Waiting is a highly anxiety-provoking time, and nurses play a vital role in supporting patients.",[265],"Bronchial Fibroscopy",[267,268],"virtual reality headset","anxiety",{"date":246,"type":35},{"date":271,"type":35},"2025-02-27",{"date":273,"type":21},"2026-02-27",{"name":41,"class":42},{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":43},"100579511","assessment-of-the-psychosocial-sexual-health-competencies-of-young-adults-born-in-france-including-those-whose-parents-were-born-abroad-and-proposal-of-a-sexual-health-promotion-model-adapted-to-the-needs-identified-100579511","NCT06825247","Assessment of the Psychosocial Sexual Health Competencies of Young Adults Born in France (including Those Whose Parents Were Born Abroad), and Proposal of a Sexual Health Promotion Model Adapted to the Needs Identified.","ECOSSE","Inclusion Criteria:\n\n* Aged from 18 to 29 years\n* Born in France or its territories,\n* Be able to read and write French.\n\nExclusion Criteria:\n\n* They are under guardianship,\n* They refuse to take part in the study.","29 Years",{"count":284,"type":21},1500,"Every year, between 4,000 and 6,000 people discover their seropositivity to the human immunodeficiency virus (HIV). The dynamics of new discoveries vary according to sexual orientation and birthplace. MSM born in France show the sharpest improvement, while heterosexuals born in France show a more moderate decline, and intravenous drug users (IDUs) are still at a low ebb.\n\nThere is little fine-grained data available on a national scale to explain these dynamics among people living with HIV (PLHIV).\n\nThe acquisition of Psychosocial Competencies in sexual health is a prerequisite for good sexual health. It is important for all young people, and all the more so for young people from immigrant backgrounds, whom we hypothesize, despite the limited existing literature, to be more vulnerable due to the influence of their origins, their parents' culture or language barrier, or even religion.\n\nThe primary research question: What psychosocial skills should be included in a sexual health education program for young people born in France (including those born to migrant parents), to enable them to enjoy good sexual health in adulthood?",[287],"Sexual Health",[289,290],"sexual health","psychosocial skills","2025-02-10",{"date":293,"type":35},"2025-02-13",{"date":295,"type":35},"2022-06-01",{"date":297,"type":21},"2025-11",{"name":41,"class":42},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":312,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":70},"100443614","prediction-of-chronic-kidney-disease-following-pre-eclampsia-diagnosis-and-early-care-100443614","NCT05056701","Prediction of Chronic Kidney Disease Following Pre-eclampsia: Diagnosis and Early Care","PRECEDE","Inclusion Criteria:\n\n* Meeting the preeclampsia criteria or one of its complications (eclampsia, HELLP syndrome) according to the ISSHP 2018 definitions within the last 5 years\n* Having signed the informed consent\n* Person affiliated to social security\n\nExclusion Criteria:\n\n* Patient with mental disability or language barrier preventing understanding of the study or consent\n* Person deprived of liberty by judicial or administrative decision\n* Person under forced psychiatric care\n* Person subject to a legal protection measure",{"count":307,"type":21},400,[55],"Pre-eclampsia (PE) is a pregnancy-associated syndrome of variable severity, classically defined by the combination of hypertension and proteinuria in a previously non-hypertensive or proteinuric patient. These symptoms normally resolve within 2-3 months after delivery regardless of the severity of the pre-eclampsia.\n\nRegardless of its definition, preeclampsia is associated with an increased risk of obstetric events and, for the mother, an increased risk of developing chronic kidney disease (CKD), hypertension, diabetes and cardiovascular disease in the broad sense.\n\nThe relationship between preeclampsia and Chronic Kidney Disease is, however, complex and not fully understood.\n\nInvestigator proposes an interventional study to identify the diagnosis of Chronic Kidney Disease in patients who have developed an episode of Preeclampsia.",[311],"Preeclampsia",[313,314],"chronic kidney disease (CKD)","preeclampsia","2024-08-30",{"date":317,"type":35},"2024-09-04",{"date":319,"type":35},"2022-05-30",{"date":321,"type":21},"2037-05-30",{"name":41,"class":42},{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":332,"conditions":333,"keywords":335,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":344,"locationsCount":252},"100538879","acceleration-time-assessment-for-prediction-of-critical-limb-ischemia-100538879","NCT06296576","Acceleration Time Assessment for Prediction of Critical Limb Ischemia","ATACLI","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Patient referred to the vascular medicine department of one of the investigating centres for arterial Doppler ultrasound of at least one lower limb and for whom a measurement of the systolic pressure index at the toe will be performed.\n* Presence of proven arterial disease, asymptomatic or not, defined by the presence of one of the following criteria:\n\n  * Rest ankle systolic pressure index ≤ 0.90\n  * Rest toe systolic pressure index ≤ 0.70\n\nExclusion Criteria:\n\n* Patient with haemodynamic instability, unable to tolerate a delay in therapeutic management caused by the ultrasound examination and measurement of systolic pressure at the toe;\n* Patients with surgical management of the lower limb (in relation to lower limb arteriopathy), already scheduled at the time of inclusion.\n* Patients with a life expectancy of less than 24 hours;\n* History of transmetatarsal amputation or amputation at a more proximal level compromising the measurement of systolic pressure and occlusion at the toe and\u002For TCPO2;\n* Refusal to participate",{"count":331,"type":21},431,"Critical Limb Ischaemia (CLI), the final stage of arterial disease, is a therapeutic emergency whose prognosis depends largely on the time taken to diagnose it. The growing prevalence of this condition and the associated healthcare costs make it an important public health objective. Diagnostic criteria for Critical Limb Ischaemia differ between learned societies and countries.\n\nIts diagnosis is most frequently based on the combination of a clinical criterion (ischaemic decubitus pain and\u002For necrotic wounds, with a time to onset \\> 2 weeks) and a haemodynamic criterion (ankle systolic pressure (ASP) \\\u003C 50mmHg or toe systolic pressure (TSP) \\\u003C 30 mmHg or transcutaneous oxygen pressure (TCPO2) \\\u003C 30 mmHg).\n\nRecent studies have highlighted the importance of pulsed Doppler flow analysis in quantifying arteriopathy of the lower limbs, both by systematically analysing flow modulation and by measuring the systolic rise time of distal arteries (dorsal artery of the foot and lateral plantar artery).\n\nThe main aim of this study is therefore to validate a reliable and accessible diagnostic tool for screening patients suffering from CLI so that they can be referred to a reference centre as early as possible.",[334],"Critical Limb Ischemia",[336,337],"systolic rise time","critical limb ischaemia","2024-08-27",{"date":340,"type":35},"2024-08-29",{"date":342,"type":35},"2024-07-01",{"date":37,"type":21},{"name":41,"class":42},{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":352,"enrollmentInfo":353,"targetDuration":4,"studyType":22,"phases":355,"briefSummary":356,"conditions":357,"keywords":360,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":43},"100521308","weight-loss-following-an-episode-of-pre-eclampsia-using-a-dissociated-or-hypocaloric-diet-in-overweight-or-obese-patients-100521308","NCT06067906","Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients","POPADIPE","Inclusion Criteria:\n\n* Person affiliated to social security\n* Free, informed and written consent signed by the participant and the investigator (no later than the day of day of inclusion and before any examination required by the research)\n* Patient over 18 years of age at the time of inclusion and \\\u003C 45 years of age\n* Having had an pre-eclampsia in the last 5 years according to the definitions of the ISSHP 2018\n* Patient with a BMI between 25 kg\u002Fm² and 40 kg\u002Fm² who accepts dietetic follow up\n* Patient with a medical prescription for dietetic follow-up aimed at losing weight loss\n* Patient with a balanced diet\n\nExclusion Criteria:\n\n* Patients with a mental disability or language barrier that prevents them from understanding or consenting to the study\n* Patients deprived of their liberty by judicial or administrative decision\n* Patients under psychiatric care\n* Patients subject to a legal protection measure\n* Patients with cognitive disorders or defined eating disorders\n* Patients who are pregnant or breast-feeding\n* Patients undergoing steroid treatment and\u002For immunosuppression\n* Have been on a low-calorie or dissociated diet for at least 6 months\n* Patients with CKD stage ≥ 3A","45 Years",{"count":354,"type":21},60,[55],"In view of the known link between pre-eclampsia, overweight\u002Fobesity and chronic kidney disease, the aim is to offer for obese and overweight patients to reduce their BMI without reducing lean body mass.\n\nThe POPADIPE project will make it possible to limit overweight or obesity by means of nutritional management chosen by the patient (hypocaloric or a dissociated diet). The latter has been the subject of little scientific investigation, particularly in relation to the management of post-pre-eclampsia.",[358,359],"Pre-Eclampsia","Obesity",[361,362,363],"pre-eclampsia","obesity","dissociated diet",{"date":365,"type":35},"2024-08-28",{"date":367,"type":35},"2023-11-02",{"date":369,"type":21},"2028-11-02",{"name":41,"class":42},{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":22,"phases":381,"briefSummary":382,"conditions":383,"keywords":385,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":389,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":43},"100509610","impact-of-the-choice-of-gastric-tube-placement-sites-on-the-incidence-of-ventilator-associated-pneumonia-100509610","NCT05915663","Impact of the Choice of Gastric Tube Placement Sites on the Incidence of Ventilator Associated Pneumonia","Impact of the Choice of Gastric Tube Placement Sites on the Incidence of Ventilator Associated Pneumonia and Other Complications in the Intensive Care Unit","SONG","Inclusion Criteria:\n\n* patient in intensive care, intubated, ventilated\n* Adult\n* Requiring a gastric tube\n* With an expected duration of mechanical ventilation of more than 48 hours\n* Affiliated to social security\n* Patient or relative consent or, failing that, emergency inclusion of the patient\n\nExclusion Criteria:\n\n* Pregnant, breast-feeding or parturient women\n* Patients under legal protection: curatorship and guardianship\n* Contraindication to placing a gastric tube through the nose or mouth\n* Patients who already have a gastric tube when they enter the service\n* Patient intubated for more than 24 hours\n* Patient intubated via the nasotracheal route",{"count":380,"type":21},2400,[55],"In intensive care, many gastric tubes are inserted on a regular basis. There are different practices in terms of the location of the gastric tube. In some cases, the tube is inserted through the nose and in others, it is inserted through the mouth.\n\nIn the literature and in practice, these gastric tubes create discomfort and complications that have an impact not only on the patient, but also on the treatments and the length of the patient's stay in hospital.\n\nNosocomial Ventilator Associated Pneumonia is the most serious common complication for patients intubated with a gastric tube. It is possible that placement site may have an impact on the risk of developing Ventilator Associated Pneumonia, particularly by increasing the risk of bacterial pullulation opposite the sinuses when the tube is placed via the nasal route.\n\nInvestigator hypothesises that placing the gastric tube orally will reduce the rate of ventilator-associated pneumonia compared with the nasal route in mechanically ventilated intensive care patients.",[384],"Intubated Patient Requiring a Gastric Tube",[386,387,388],"orogastric tube","nasogastric tube","Ventilator Associated Pneumonia",{"date":340,"type":35},{"date":391,"type":21},"2024-10-01",{"date":393,"type":21},"2027-03-01",{"name":41,"class":42},{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":22,"phases":404,"briefSummary":405,"conditions":406,"keywords":408,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":417,"locationsCount":70},"100496400","description-of-septic-thrombophlebitis-on-central-venous-catheter-and-midline-100496400","NCT05743738","Description of Septic Thrombophlebitis on Central Venous Catheter and Midline","THROMBOSEP","Inclusion Criteria:\n\n* Adult patient hospitalised at the CHM or CHUA, with a central venous device (Implantable chamber, central venous jugular, femoral, subclavian, PICCline, dialysis catheter) or a Midline and having catheter-related bacteremia\n* Catheter-related bacteremia according to the following definition (ePOPI): Positive blood cultures within 48 hours of a suspected catheter infection (or its removal) With one of the following criteria: - Before catheter removal: differential time of positivity of central\u002Fperipheral blood cultures ≥ 2 hours\n* After catheter removal: positive catheter culture ≥ 103 CFU\u002Fml, with the same organism.\n* Patient transportable for ultrasound or ultrasound can be performed in the patient's bed\n* Patient capable of giving consent, or consent of the trusted person for patients not capable of giving consent at the time of inclusion\n* Written consent signed by the participant and the investigator\n* Person affiliated to social security\n\nExclusion Criteria:\n\n* Patient with a life expectancy of less than one month\n* Contraindication to anticoagulation\n* Patient already on curative anticoagulant therapy for any indication\n* Minor or adult patient under guardianship or protected or deprived of liberty\n* Pregnant, nursing or parturient woman",{"count":403,"type":21},120,[55],"Central venous catheters improve the tolerability and feasibility of patient care in the hospital setting by allowing the administration of hyper-osmotic, vesicant and venotoxic fluids. Despite these advantages, the long-term presence of central venous catheters is associated with thrombotic and infectious risks , including catheter-related bacteremia, which can be complicated by septic thrombophlebitis and endocarditis that can lead to death.\n\nSeptic thrombophlebitis is a complication of venous catheter infections, which increases the morbidity. It is defined by the presence of a thrombosis in the vein where the venous catheter is located, associated with a bacteremia. A distinction is made between superficial and deep thrombophlebitis.\n\nThe frequency of septic thrombophlebitis of venous catheters is variable and poorly described in the literature.\n\nWhen the diagnosis of septic thrombophlebitis is made, it is recommended to extend the duration of antibiotic therapy, to remove the infected catheter and to prescribe anticoagulant treatment. However, there is no recommendation on the duration of anticoagulation for septic thrombophlebitis, whether it is deep or superficial.\n\nInvestigator proposes a prospective and descriptive interventional study to describe the ultrasound evolution of thrombus in patients with septic thrombophlebitis on central venous catheter and midline.",[407],"Septic Thrombophlebitis",[409,410],"septic thrombophlebitis","Doppler ultrasound","2023-06-14",{"date":413,"type":35},"2023-06-15",{"date":415,"type":35},"2023-05-31",{"date":62,"type":21},{"name":41,"class":42},{"id":419,"slug":420,"hasResults":11,"nctId":421,"briefTitle":422,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":425,"targetDuration":427,"studyType":151,"phases":4,"briefSummary":428,"conditions":429,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":43},"100423930","evaluation-of-patient-satisfaction-and-therapeutic-impact-regarding-joint-consultation-rheumatologistdermatologist-100423930","NCT04800289","Evaluation of Patient Satisfaction and Therapeutic Impact Regarding Joint Consultation Rheumatologist\u002FDermatologist","RHUMPSO","Inclusion Criteria:\n\n* All patients received in a joint rheumatologist\u002Fdermatologist consultation at the Le Mans Hospital\n\nExclusion Criteria:\n\n* Diagnosis of psoriatic arthritis not retained",{"count":426,"type":21},600,"5 Years","Current increase in the number of multidisciplinary consultations, but little documentation on their impact on patient management. More specifically, in the context of psoriatic arthritis, we are seeking to investigate the interest for the patient, through his or her satisfaction and the evolution of the activity of his or her pathology, of a global, joint management in Rheumatology and Dermatology.",[430],"Psoriatic Arthritis","2021-03-12",{"date":433,"type":35},"2021-03-16",{"date":435,"type":35},"2020-07-19",{"date":437,"type":21},"2030-07-31",{"name":41,"class":42},""]